链激酶静脉注射已广泛用于治疗心肌梗死及局限性胸膜渗出 ,已知该给药途径可产生抗链激酶抗体。本研究旨在探讨链激酶胸膜内给药是否会产生抗链激酶抗体。若局限性胸膜渗出发展为心肌梗死 ,用链激酶治疗时产生抗链激酶抗体 ,或许具有重要的临床意义。其次 ,本研究还评价了治疗 Intravenous streptokinase has been widely used to treat myocardial infarction and localized pleural exudation, which is known to produce anti-streptokinase antibodies. The purpose of this study was to investigate whether streptokinase can produce anti-streptokinase antibodies in the pleural cavity. If the limitations of pleural effusion developed myocardial infarction, streptokinase therapy with anti-streptokinase antibodies, may have important clinical significance. Second, the study also evaluated treatment